For the quarter ended June 2026, Becton Dickinson (BDX Quick QuoteBDX - Free Report) reported revenue of $4.98 billion, down 9.6% over the same period last year. EPS came in at $3.23, compared to $3.68 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $4.89 billion, representing a surprise of +1.81%. The company delivered an EPS surprise of +2.87%, with the consensus EPS estimate being $3.14.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Becton Dickinson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Connected Care- Medication Management Solutions- International: $178 million versus the two-analyst average estimate of $178.72 million. The reported number represents a year-over-year change of -0.6%.
• Revenues- Interventional- Surgery- International: $116 million versus $111.26 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.9% change.
• Revenues- Interventional- United States: $957 million compared to the $947.23 million average estimate based on two analysts. The reported number represents a change of +6.6% year over year.
• Revenues- Connected Care- Medication Management Solutions- United States: $737 million compared to the $711.11 million average estimate based on two analysts. The reported number represents a change of +4% year over year.
• Revenues- Interventional: $1.41 billion versus the three-analyst average estimate of $1.39 billion. The reported number represents a year-over-year change of +6.5%.
• Revenues- Interventional- Surgery: $422 million versus the three-analyst average estimate of $417.5 million. The reported number represents a year-over-year change of +6.8%.
• Revenues- Interventional- Peripheral Intervention: $552 million versus $528.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.8% change.
• Revenues- Interventional- Urology and Critical Care: $440 million versus $447.64 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.3% change.
• Revenues- Medical Essentials- Medication Delivery Solutions: $1.16 billion compared to the $1.17 billion average estimate based on three analysts.
• Revenues- Connected Care- Medication Management Solutions: $915 million versus $896.89 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3% change.
• Revenues- Connected Care: $1.22 billion compared to the $1.2 billion average estimate based on three analysts.
• Revenues- Connected Care- Advanced Patient Monitoring: $309 million compared to the $301.13 million average estimate based on three analysts.

View all Key Company Metrics for Becton Dickinson here>>>

Shares of Becton Dickinson have returned +13.4% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.